These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 23047356)
1. The FDA Safety and Innovation Act. Steinbrook R; Sharfstein JM JAMA; 2012 Oct; 308(14):1437-8. PubMed ID: 23047356 [No Abstract] [Full Text] [Related]
2. User fees and beyond--the FDA Safety and Innovation Act of 2012. Kramer DB; Kesselheim AS N Engl J Med; 2012 Oct; 367(14):1277-9. PubMed ID: 23034017 [No Abstract] [Full Text] [Related]
3. Pharmaceuticals and medical devices: FDA oversight. Chaps NA Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718 [No Abstract] [Full Text] [Related]
4. US lawmakers tackle safety reforms at the FDA. Zwillich T Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942 [No Abstract] [Full Text] [Related]
5. Drug safety reform at the FDA--pendulum swing or systematic improvement? McClellan M N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081 [No Abstract] [Full Text] [Related]
6. What ails the FDA? Okie S N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660 [No Abstract] [Full Text] [Related]
8. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief. Chaps NA Issue Brief Health Policy Track Serv; 2008 Jan; ():1-18. PubMed ID: 18345557 [No Abstract] [Full Text] [Related]
9. PDUFA reauthorization--drug safety's golden moment of opportunity? Hennessy S; Strom BL N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082 [No Abstract] [Full Text] [Related]
10. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration? Zelenay JL Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773 [No Abstract] [Full Text] [Related]
11. Economic Impacts of the Generic Drug User Fee Act Fee Structure. Dong K; Boehm G; Zheng Q Value Health; 2017 Jun; 20(6):792-798. PubMed ID: 28577697 [TBL] [Abstract][Full Text] [Related]
12. Pharmaceuticals and medical devices: FDA oversight. Issue brief. Berry MD Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449 [No Abstract] [Full Text] [Related]
14. Paying for drug approvals--who's using whom? Avorn J N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083 [No Abstract] [Full Text] [Related]
15. FDA dependence on drug industry. Lawson GW J Natl Med Assoc; 2005 Jul; 97(7):1039-40. PubMed ID: 16080677 [No Abstract] [Full Text] [Related]
16. Therapeutic-class wars--drug promotion in a competitive marketplace. Kessler DA; Rose JL; Temple RJ; Schapiro R; Griffin JP N Engl J Med; 1994 Nov; 331(20):1350-3. PubMed ID: 7935706 [No Abstract] [Full Text] [Related]
17. Pharmaceuticals and medical devices: FDA oversight. Berry MD Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893 [No Abstract] [Full Text] [Related]
18. FDA user fees and innovation. Somberg J Am J Ther; 2008; 15(2):97. PubMed ID: 18356626 [No Abstract] [Full Text] [Related]
19. Pharmaceutical and Medical Devices: FDA Oversight. White RS; Issue Brief Health Policy Track Serv; 2015 Dec; ():1-97. PubMed ID: 27116797 [No Abstract] [Full Text] [Related]
20. FDA and drug safety: new Tufts study challenges critics of the Prescription Drug User Fee Act. Lee R J Law Med Ethics; 2006; 34(1):131-4. PubMed ID: 16489994 [No Abstract] [Full Text] [Related] [Next] [New Search]